Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis.

He A, Song D, Zhang L, Li C.

J Headache Pain. 2017 Dec;18(1):26. doi: 10.1186/s10194-017-0720-7. Epub 2017 Feb 20.

2.

Clinical Response to Valproate in Patients with Migraine.

Ichikawa M, Katoh H, Kurihara T, Ishii M.

J Clin Neurol. 2016 Oct;12(4):468-475. doi: 10.3988/jcn.2016.12.4.468.

3.

Evidence-Based Treatments for Adults with Migraine.

Gooriah R, Nimeri R, Ahmed F.

Pain Res Treat. 2015;2015:629382. doi: 10.1155/2015/629382. Epub 2015 Dec 29. Review.

4.

sec-Butylpropylacetamide (SPD) has antimigraine properties.

Kaufmann D, Bates EA, Yagen B, Bialer M, Saunders GH, Wilcox K, White HS, Brennan KC.

Cephalalgia. 2016 Sep;36(10):924-35. doi: 10.1177/0333102415612773. Epub 2015 Nov 13.

PMID:
26568161
5.

A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.

Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J.

PLoS One. 2015 Jul 14;10(7):e0130733. doi: 10.1371/journal.pone.0130733. eCollection 2015.

6.

Preventive pharmacologic treatments for episodic migraine in adults.

Shamliyan TA, Choi JY, Ramakrishnan R, Miller JB, Wang SY, Taylor FR, Kane RL.

J Gen Intern Med. 2013 Sep;28(9):1225-37. doi: 10.1007/s11606-013-2433-1. Epub 2013 Apr 17.

7.

Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P.

Patient Relat Outcome Meas. 2010 Jul;1:107-18. doi: 10.2147/PROM.S9742. Epub 2010 Sep 17.

8.

Prophylaxis of migraine headache.

Pringsheim T, Davenport WJ, Becker WJ.

CMAJ. 2010 Apr 20;182(7):E269-76. doi: 10.1503/cmaj.081657. Epub 2010 Feb 16. Review. No abstract available.

9.
10.

Investigation of gamma-aminobutyric acid (GABA) A receptors genes and migraine susceptibility.

Fernandez F, Esposito T, Lea RA, Colson NJ, Ciccodicola A, Gianfrancesco F, Griffiths LR.

BMC Med Genet. 2008 Dec 16;9:109. doi: 10.1186/1471-2350-9-109.

11.

Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate.

Togha M, Rahmat Jirde M, Nilavari K, Ashrafian H, Razeghi S, Kohan L.

J Headache Pain. 2008 Apr;9(2):77-82. doi: 10.1007/s10194-008-0013-2. Epub 2008 Feb 20. Erratum in: J Headache Pain. 2008 Aug;9(4):257. Mansoureh, Togha [corrected to Togha, Mansoureh].

12.

The effect of sodium valproate on chronic daily headache and its subgroups.

Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F.

J Headache Pain. 2008 Feb;9(1):37-41. doi: 10.1007/s10194-008-0002-5. Epub 2008 Jan 23.

13.
14.

The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.

Limmroth V, Michel MC.

Br J Clin Pharmacol. 2001 Sep;52(3):237-43. Review.

15.

The clinician's approach to the management of headache.

Maizels M.

West J Med. 1998 Mar;168(3):203-12. Review.

16.

Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin.

Cutrer FM, Limmroth V, Ayata G, Moskowitz MA.

Br J Pharmacol. 1995 Dec;116(8):3199-204.

17.

Diagnosis and management of migraine.

Goadsby PJ, Olesen J.

BMJ. 1996 May 18;312(7041):1279-83. Review. No abstract available.

18.

Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation.

Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Yu X, Moskowitz MA.

Br J Pharmacol. 1995 Sep;116(1):1661-7.

19.

Headache.

Raskin NH.

West J Med. 1994 Sep;161(3):299-302. Review.

Supplemental Content

Support Center